Unlike in CML where treatment-free remission is an established goal, discontinuing interferon in PV after a deep molecular response is considered theoretical and experimental. Clinicians caution against setting this as an expectation for patients, as most will require indefinite therapy to maintain control.

To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.

Interferon therapy is being evaluated in a distinct niche from JAK inhibitors. It is targeted at patients with early or low-risk myelofibrosis, not for immediate symptom control, but with the strategic goal of potentially modifying the disease course and slowing its natural progression.

To manage infection risk and improve quality of life, experts are quickly reducing bispecific antibody dosing frequency (e.g., to monthly) once a response is achieved. This real-world practice deviates from rigid trial schedules to optimize patient outcomes.

Contrary to the standard 150mg starting dose, many clinicians begin abemaciclib at 100mg BID. Data from the TRADE trial and retrospective MonarchE analyses show this improves tolerability, reduces early dropouts, and maintains efficacy, as patients who dose-reduced to 100mg performed just as well.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

Proactively, some hematologists now offer interferon-based therapy to very young, asymptomatic low-risk PV patients. The rationale is to leverage the drug's potential for disease modification by reducing JAK2 allele burden early on, even though this is not yet a formal guideline-supported indication.

Clinicians recommend starting abemaciclib at 100mg BID, rather than the standard 150mg, to mitigate initial GI toxicity. This dose-escalation approach, supported by the TRADE study, improves long-term adherence and allows more patients to reach the target dose without discontinuing.